Any feedback?
Please rate this page
(literature.php)
(0/150)

BRENDA support

Literature summary extracted from

  • Bowyer, P.; Tate, E.; Leatherbarrow, R.; Holder, A.; Smith, D.; Brown, K.
    N-myristoyltransferase: A prospective drug target for protozoan parasites (2008), ChemMedChem, 3, 402-408.
    View publication on PubMed

Application

EC Number Application Comment Organism
2.3.1.97 drug development the enzyme is a drug target Trypanosoma brucei
2.3.1.97 drug development the enzyme is a drug target Candida albicans
2.3.1.97 drug development the enzyme is a drug target Plasmodium falciparum
2.3.1.97 drug development the enzyme is a drug target Cryptococcus neoformans
2.3.1.97 drug development the enzyme is a drug target Leishmania major
2.3.1.97 drug development the enzyme is a drug target Histoplasma capsulatum

Inhibitors

EC Number Inhibitors Comment Organism Structure
2.3.1.97 (1R,3S)-N-[2-[(cyclopentylcarbonyl)amino]-1,3-benzothiazol-6-yl]-3-[(naphthalen-2-ylmethyl)amino]cyclohexanecarboxamide
-
 Candida albicans
2.3.1.97 (1R,3S)-N-[2-[(cyclopentylcarbonyl)amino]-1,3-benzothiazol-6-yl]-3-[(naphthalen-2-ylmethyl)amino]cyclohexanecarboxamide
-
 Cryptococcus neoformans
2.3.1.97 (1R,3S)-N-[2-[(cyclopentylcarbonyl)amino]-1,3-benzothiazol-6-yl]-3-[(naphthalen-2-ylmethyl)amino]cyclohexanecarboxamide
-
 Histoplasma capsulatum
2.3.1.97 (1R,3S)-N-[2-[(cyclopentylcarbonyl)amino]-1,3-benzothiazol-6-yl]-3-[(naphthalen-2-ylmethyl)amino]cyclohexanecarboxamide
-
 Leishmania major
2.3.1.97 (1R,3S)-N-[2-[(cyclopentylcarbonyl)amino]-1,3-benzothiazol-6-yl]-3-[(naphthalen-2-ylmethyl)amino]cyclohexanecarboxamide
-
 Plasmodium falciparum
2.3.1.97 (1R,3S)-N-[2-[(cyclopentylcarbonyl)amino]-1,3-benzothiazol-6-yl]-3-[(naphthalen-2-ylmethyl)amino]cyclohexanecarboxamide
-
 Saccharomyces cerevisiae
2.3.1.97 (1R,3S)-N-[2-[(cyclopentylcarbonyl)amino]-1,3-benzothiazol-6-yl]-3-[(naphthalen-2-ylmethyl)amino]cyclohexanecarboxamide
-
 Trypanosoma brucei
2.3.1.97 (4S,5aS,12aS)-2-carbamoyl-4-(dimethylamino)-3,10,12,12a-tetrahydroxy-6-methylidene-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracen-5-yl acetate
-
 Candida albicans
2.3.1.97 (4S,5aS,12aS)-2-carbamoyl-4-(dimethylamino)-3,10,12,12a-tetrahydroxy-6-methylidene-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracen-5-yl acetate
-
 Cryptococcus neoformans
2.3.1.97 (4S,5aS,12aS)-2-carbamoyl-4-(dimethylamino)-3,10,12,12a-tetrahydroxy-6-methylidene-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracen-5-yl acetate
-
 Histoplasma capsulatum
2.3.1.97 (4S,5aS,12aS)-2-carbamoyl-4-(dimethylamino)-3,10,12,12a-tetrahydroxy-6-methylidene-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracen-5-yl acetate
-
 Leishmania major
2.3.1.97 (4S,5aS,12aS)-2-carbamoyl-4-(dimethylamino)-3,10,12,12a-tetrahydroxy-6-methylidene-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracen-5-yl acetate
-
 Plasmodium falciparum
2.3.1.97 (4S,5aS,12aS)-2-carbamoyl-4-(dimethylamino)-3,10,12,12a-tetrahydroxy-6-methylidene-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracen-5-yl acetate
-
 Saccharomyces cerevisiae
2.3.1.97 (4S,5aS,12aS)-2-carbamoyl-4-(dimethylamino)-3,10,12,12a-tetrahydroxy-6-methylidene-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracen-5-yl acetate
-
 Trypanosoma brucei
2.3.1.97 1-hydroxy-2-[(1-methylethyl)amino]ethyl 2,6-dihydroxybenzoate
-
 Candida albicans
2.3.1.97 1-hydroxy-2-[(1-methylethyl)amino]ethyl 2,6-dihydroxybenzoate
-
 Cryptococcus neoformans
2.3.1.97 1-hydroxy-2-[(1-methylethyl)amino]ethyl 2,6-dihydroxybenzoate
-
 Histoplasma capsulatum
2.3.1.97 1-hydroxy-2-[(1-methylethyl)amino]ethyl 2,6-dihydroxybenzoate
-
 Leishmania major
2.3.1.97 1-hydroxy-2-[(1-methylethyl)amino]ethyl 2,6-dihydroxybenzoate
-
 Plasmodium falciparum
2.3.1.97 1-hydroxy-2-[(1-methylethyl)amino]ethyl 2,6-dihydroxybenzoate
-
 Saccharomyces cerevisiae
2.3.1.97 1-hydroxy-2-[(1-methylethyl)amino]ethyl 2,6-dihydroxybenzoate
-
 Trypanosoma brucei
2.3.1.97 2-(diethylamino)ethyl 2-[(cyclohexylcarbonyl)amino]-1,3-benzothiazole-6-carboxylate
-
 Candida albicans
2.3.1.97 2-(diethylamino)ethyl 2-[(cyclohexylcarbonyl)amino]-1,3-benzothiazole-6-carboxylate
-
 Cryptococcus neoformans
2.3.1.97 2-(diethylamino)ethyl 2-[(cyclohexylcarbonyl)amino]-1,3-benzothiazole-6-carboxylate
-
 Histoplasma capsulatum
2.3.1.97 2-(diethylamino)ethyl 2-[(cyclohexylcarbonyl)amino]-1,3-benzothiazole-6-carboxylate
-
 Leishmania major
2.3.1.97 2-(diethylamino)ethyl 2-[(cyclohexylcarbonyl)amino]-1,3-benzothiazole-6-carboxylate
-
 Plasmodium falciparum
2.3.1.97 2-(diethylamino)ethyl 2-[(cyclohexylcarbonyl)amino]-1,3-benzothiazole-6-carboxylate
-
 Saccharomyces cerevisiae
2.3.1.97 2-(diethylamino)ethyl 2-[(cyclohexylcarbonyl)amino]-1,3-benzothiazole-6-carboxylate
-
 Trypanosoma brucei
2.3.1.97 2-([[4-(aminomethyl)cyclohexyl]carbonyl]amino)-N,N-dimethyl-1,3-benzothiazole-6-carboxamide
-
 Candida albicans
2.3.1.97 2-([[4-(aminomethyl)cyclohexyl]carbonyl]amino)-N,N-dimethyl-1,3-benzothiazole-6-carboxamide
-
 Cryptococcus neoformans
2.3.1.97 2-([[4-(aminomethyl)cyclohexyl]carbonyl]amino)-N,N-dimethyl-1,3-benzothiazole-6-carboxamide
-
 Histoplasma capsulatum
2.3.1.97 2-([[4-(aminomethyl)cyclohexyl]carbonyl]amino)-N,N-dimethyl-1,3-benzothiazole-6-carboxamide
-
 Leishmania major
2.3.1.97 2-([[4-(aminomethyl)cyclohexyl]carbonyl]amino)-N,N-dimethyl-1,3-benzothiazole-6-carboxamide
-
 Plasmodium falciparum
2.3.1.97 2-([[4-(aminomethyl)cyclohexyl]carbonyl]amino)-N,N-dimethyl-1,3-benzothiazole-6-carboxamide
-
 Saccharomyces cerevisiae
2.3.1.97 2-([[4-(aminomethyl)cyclohexyl]carbonyl]amino)-N,N-dimethyl-1,3-benzothiazole-6-carboxamide
-
 Trypanosoma brucei
2.3.1.97 2-[([(1R,3S)-3-[(1-benzofuran-6-ylmethyl)amino]cyclohexyl]carbonyl)amino]-N,N-dimethyl-1,3-benzothiazole-6-carboxamide
-
 Candida albicans
2.3.1.97 2-[([(1R,3S)-3-[(1-benzofuran-6-ylmethyl)amino]cyclohexyl]carbonyl)amino]-N,N-dimethyl-1,3-benzothiazole-6-carboxamide
-
 Cryptococcus neoformans
2.3.1.97 2-[([(1R,3S)-3-[(1-benzofuran-6-ylmethyl)amino]cyclohexyl]carbonyl)amino]-N,N-dimethyl-1,3-benzothiazole-6-carboxamide
-
 Histoplasma capsulatum
2.3.1.97 2-[([(1R,3S)-3-[(1-benzofuran-6-ylmethyl)amino]cyclohexyl]carbonyl)amino]-N,N-dimethyl-1,3-benzothiazole-6-carboxamide
-
 Leishmania major
2.3.1.97 2-[([(1R,3S)-3-[(1-benzofuran-6-ylmethyl)amino]cyclohexyl]carbonyl)amino]-N,N-dimethyl-1,3-benzothiazole-6-carboxamide
-
 Plasmodium falciparum
2.3.1.97 2-[([(1R,3S)-3-[(1-benzofuran-6-ylmethyl)amino]cyclohexyl]carbonyl)amino]-N,N-dimethyl-1,3-benzothiazole-6-carboxamide
-
 Saccharomyces cerevisiae
2.3.1.97 2-[([(1R,3S)-3-[(1-benzofuran-6-ylmethyl)amino]cyclohexyl]carbonyl)amino]-N,N-dimethyl-1,3-benzothiazole-6-carboxamide
-
 Trypanosoma brucei
2.3.1.97 2-[([(1R,3S)-3-[(1H-indol-6-ylmethyl)amino]cyclohexyl]acetyl)amino]-N,N-dimethyl-1,3-benzothiazole-6-carboxamide
-
 Candida albicans
2.3.1.97 2-[([(1R,3S)-3-[(1H-indol-6-ylmethyl)amino]cyclohexyl]acetyl)amino]-N,N-dimethyl-1,3-benzothiazole-6-carboxamide
-
 Cryptococcus neoformans
2.3.1.97 2-[([(1R,3S)-3-[(1H-indol-6-ylmethyl)amino]cyclohexyl]acetyl)amino]-N,N-dimethyl-1,3-benzothiazole-6-carboxamide
-
 Histoplasma capsulatum
2.3.1.97 2-[([(1R,3S)-3-[(1H-indol-6-ylmethyl)amino]cyclohexyl]acetyl)amino]-N,N-dimethyl-1,3-benzothiazole-6-carboxamide
-
 Leishmania major
2.3.1.97 2-[([(1R,3S)-3-[(1H-indol-6-ylmethyl)amino]cyclohexyl]acetyl)amino]-N,N-dimethyl-1,3-benzothiazole-6-carboxamide
-
 Plasmodium falciparum
2.3.1.97 2-[([(1R,3S)-3-[(1H-indol-6-ylmethyl)amino]cyclohexyl]acetyl)amino]-N,N-dimethyl-1,3-benzothiazole-6-carboxamide
-
 Saccharomyces cerevisiae
2.3.1.97 2-[([(1R,3S)-3-[(1H-indol-6-ylmethyl)amino]cyclohexyl]acetyl)amino]-N,N-dimethyl-1,3-benzothiazole-6-carboxamide
-
 Trypanosoma brucei
2.3.1.97 3,3'-[(3-carboxy-4-oxocyclohexa-2,5-dien-1-ylidene)methanediyl]bis(6-hydroxybenzoic acid)
-
 Candida albicans
2.3.1.97 3,3'-[(3-carboxy-4-oxocyclohexa-2,5-dien-1-ylidene)methanediyl]bis(6-hydroxybenzoic acid)
-
 Cryptococcus neoformans
2.3.1.97 3,3'-[(3-carboxy-4-oxocyclohexa-2,5-dien-1-ylidene)methanediyl]bis(6-hydroxybenzoic acid)
-
 Histoplasma capsulatum
2.3.1.97 3,3'-[(3-carboxy-4-oxocyclohexa-2,5-dien-1-ylidene)methanediyl]bis(6-hydroxybenzoic acid)
-
 Leishmania major
2.3.1.97 3,3'-[(3-carboxy-4-oxocyclohexa-2,5-dien-1-ylidene)methanediyl]bis(6-hydroxybenzoic acid)
-
 Plasmodium falciparum
2.3.1.97 3,3'-[(3-carboxy-4-oxocyclohexa-2,5-dien-1-ylidene)methanediyl]bis(6-hydroxybenzoic acid)
-
 Saccharomyces cerevisiae
2.3.1.97 3,3'-[(3-carboxy-4-oxocyclohexa-2,5-dien-1-ylidene)methanediyl]bis(6-hydroxybenzoic acid)
-
 Trypanosoma brucei
2.3.1.97 3-([3-methyl-2-[(2,3,4-trifluorophenoxy)methyl]-1-benzofuran-4-yl]oxy)-N-(pyridin-3-ylmethyl)propan-1-amine
-
 Candida albicans
2.3.1.97 3-([3-methyl-2-[(2,3,4-trifluorophenoxy)methyl]-1-benzofuran-4-yl]oxy)-N-(pyridin-3-ylmethyl)propan-1-amine
-
 Cryptococcus neoformans
2.3.1.97 3-([3-methyl-2-[(2,3,4-trifluorophenoxy)methyl]-1-benzofuran-4-yl]oxy)-N-(pyridin-3-ylmethyl)propan-1-amine
-
 Histoplasma capsulatum
2.3.1.97 3-([3-methyl-2-[(2,3,4-trifluorophenoxy)methyl]-1-benzofuran-4-yl]oxy)-N-(pyridin-3-ylmethyl)propan-1-amine
-
 Leishmania major
2.3.1.97 3-([3-methyl-2-[(2,3,4-trifluorophenoxy)methyl]-1-benzofuran-4-yl]oxy)-N-(pyridin-3-ylmethyl)propan-1-amine
-
 Plasmodium falciparum
2.3.1.97 3-([3-methyl-2-[(2,3,4-trifluorophenoxy)methyl]-1-benzofuran-4-yl]oxy)-N-(pyridin-3-ylmethyl)propan-1-amine
-
 Saccharomyces cerevisiae
2.3.1.97 3-([3-methyl-2-[(2,3,4-trifluorophenoxy)methyl]-1-benzofuran-4-yl]oxy)-N-(pyridin-3-ylmethyl)propan-1-amine
-
 Trypanosoma brucei
2.3.1.97 4-(4,5-dihydroxy-9-methyl-3-oxo-1,3,3a,4,9,9a-hexahydronaphtho[2,3-c]furan-1-yl)-2,5,6-trihydroxycyclohexa-2,4-diene-1-carboxamide
-
 Candida albicans
2.3.1.97 4-(4,5-dihydroxy-9-methyl-3-oxo-1,3,3a,4,9,9a-hexahydronaphtho[2,3-c]furan-1-yl)-2,5,6-trihydroxycyclohexa-2,4-diene-1-carboxamide
-
 Cryptococcus neoformans
2.3.1.97 4-(4,5-dihydroxy-9-methyl-3-oxo-1,3,3a,4,9,9a-hexahydronaphtho[2,3-c]furan-1-yl)-2,5,6-trihydroxycyclohexa-2,4-diene-1-carboxamide
-
 Histoplasma capsulatum
2.3.1.97 4-(4,5-dihydroxy-9-methyl-3-oxo-1,3,3a,4,9,9a-hexahydronaphtho[2,3-c]furan-1-yl)-2,5,6-trihydroxycyclohexa-2,4-diene-1-carboxamide
-
 Leishmania major
2.3.1.97 4-(4,5-dihydroxy-9-methyl-3-oxo-1,3,3a,4,9,9a-hexahydronaphtho[2,3-c]furan-1-yl)-2,5,6-trihydroxycyclohexa-2,4-diene-1-carboxamide
-
 Plasmodium falciparum
2.3.1.97 4-(4,5-dihydroxy-9-methyl-3-oxo-1,3,3a,4,9,9a-hexahydronaphtho[2,3-c]furan-1-yl)-2,5,6-trihydroxycyclohexa-2,4-diene-1-carboxamide
-
 Saccharomyces cerevisiae
2.3.1.97 4-(4,5-dihydroxy-9-methyl-3-oxo-1,3,3a,4,9,9a-hexahydronaphtho[2,3-c]furan-1-yl)-2,5,6-trihydroxycyclohexa-2,4-diene-1-carboxamide
-
 Trypanosoma brucei
2.3.1.97 cis-4-[(naphthalen-2-ylmethyl)amino]-N-(6-pyridin-2-yl-1,3-benzothiazol-2-yl)cyclohexanecarboxamide
-
 Candida albicans
2.3.1.97 cis-4-[(naphthalen-2-ylmethyl)amino]-N-(6-pyridin-2-yl-1,3-benzothiazol-2-yl)cyclohexanecarboxamide
-
 Cryptococcus neoformans
2.3.1.97 cis-4-[(naphthalen-2-ylmethyl)amino]-N-(6-pyridin-2-yl-1,3-benzothiazol-2-yl)cyclohexanecarboxamide
-
 Histoplasma capsulatum
2.3.1.97 cis-4-[(naphthalen-2-ylmethyl)amino]-N-(6-pyridin-2-yl-1,3-benzothiazol-2-yl)cyclohexanecarboxamide
-
 Leishmania major
2.3.1.97 cis-4-[(naphthalen-2-ylmethyl)amino]-N-(6-pyridin-2-yl-1,3-benzothiazol-2-yl)cyclohexanecarboxamide
-
 Plasmodium falciparum
2.3.1.97 cis-4-[(naphthalen-2-ylmethyl)amino]-N-(6-pyridin-2-yl-1,3-benzothiazol-2-yl)cyclohexanecarboxamide
-
 Saccharomyces cerevisiae
2.3.1.97 cis-4-[(naphthalen-2-ylmethyl)amino]-N-(6-pyridin-2-yl-1,3-benzothiazol-2-yl)cyclohexanecarboxamide
-
 Trypanosoma brucei
2.3.1.97 cis-N-(6-fluoro-1,3-benzothiazol-2-yl)-4-[(naphthalen-2-ylmethyl)amino]cyclohexanecarboxamide
-
 Candida albicans
2.3.1.97 cis-N-(6-fluoro-1,3-benzothiazol-2-yl)-4-[(naphthalen-2-ylmethyl)amino]cyclohexanecarboxamide
-
 Cryptococcus neoformans
2.3.1.97 cis-N-(6-fluoro-1,3-benzothiazol-2-yl)-4-[(naphthalen-2-ylmethyl)amino]cyclohexanecarboxamide
-
 Histoplasma capsulatum
2.3.1.97 cis-N-(6-fluoro-1,3-benzothiazol-2-yl)-4-[(naphthalen-2-ylmethyl)amino]cyclohexanecarboxamide
-
 Leishmania major
2.3.1.97 cis-N-(6-fluoro-1,3-benzothiazol-2-yl)-4-[(naphthalen-2-ylmethyl)amino]cyclohexanecarboxamide
-
 Plasmodium falciparum
2.3.1.97 cis-N-(6-fluoro-1,3-benzothiazol-2-yl)-4-[(naphthalen-2-ylmethyl)amino]cyclohexanecarboxamide
-
 Saccharomyces cerevisiae
2.3.1.97 cis-N-(6-fluoro-1,3-benzothiazol-2-yl)-4-[(naphthalen-2-ylmethyl)amino]cyclohexanecarboxamide
-
 Trypanosoma brucei
2.3.1.97 cis-N-1,3-benzothiazol-2-yl-4-[(naphthalen-2-ylmethyl)amino]cyclohexanecarboxamide
-
 Candida albicans
2.3.1.97 cis-N-1,3-benzothiazol-2-yl-4-[(naphthalen-2-ylmethyl)amino]cyclohexanecarboxamide
-
 Cryptococcus neoformans
2.3.1.97 cis-N-1,3-benzothiazol-2-yl-4-[(naphthalen-2-ylmethyl)amino]cyclohexanecarboxamide
-
 Histoplasma capsulatum
2.3.1.97 cis-N-1,3-benzothiazol-2-yl-4-[(naphthalen-2-ylmethyl)amino]cyclohexanecarboxamide
-
 Leishmania major
2.3.1.97 cis-N-1,3-benzothiazol-2-yl-4-[(naphthalen-2-ylmethyl)amino]cyclohexanecarboxamide
-
 Plasmodium falciparum
2.3.1.97 cis-N-1,3-benzothiazol-2-yl-4-[(naphthalen-2-ylmethyl)amino]cyclohexanecarboxamide
-
 Saccharomyces cerevisiae
2.3.1.97 cis-N-1,3-benzothiazol-2-yl-4-[(naphthalen-2-ylmethyl)amino]cyclohexanecarboxamide
-
 Trypanosoma brucei
2.3.1.97 ethyl 3-methyl-4-[3-[(pyridin-3-ylmethyl)amino]propoxy]-1-benzofuran-2-carboxylate
-
 Candida albicans
2.3.1.97 ethyl 3-methyl-4-[3-[(pyridin-3-ylmethyl)amino]propoxy]-1-benzofuran-2-carboxylate
-
 Cryptococcus neoformans
2.3.1.97 ethyl 3-methyl-4-[3-[(pyridin-3-ylmethyl)amino]propoxy]-1-benzofuran-2-carboxylate
-
 Histoplasma capsulatum
2.3.1.97 ethyl 3-methyl-4-[3-[(pyridin-3-ylmethyl)amino]propoxy]-1-benzofuran-2-carboxylate
-
 Leishmania major
2.3.1.97 ethyl 3-methyl-4-[3-[(pyridin-3-ylmethyl)amino]propoxy]-1-benzofuran-2-carboxylate
-
 Plasmodium falciparum
2.3.1.97 ethyl 3-methyl-4-[3-[(pyridin-3-ylmethyl)amino]propoxy]-1-benzofuran-2-carboxylate
-
 Saccharomyces cerevisiae
2.3.1.97 ethyl 3-methyl-4-[3-[(pyridin-3-ylmethyl)amino]propoxy]-1-benzofuran-2-carboxylate
-
 Trypanosoma brucei
2.3.1.97 additional information inhibitor design and development, overview Candida albicans
2.3.1.97 additional information inhibitor design and development, overview Cryptococcus neoformans
2.3.1.97 additional information inhibitor design and development, overview Histoplasma capsulatum
2.3.1.97 additional information inhibitor design and development, overview Leishmania major
2.3.1.97 additional information inhibitor design and development, overview Plasmodium falciparum
2.3.1.97 additional information inhibitor design and development, overview Saccharomyces cerevisiae
2.3.1.97 additional information inhibitor design and development, overview Trypanosoma brucei
2.3.1.97 N-([4-[5-(2-methyl-1H-imidazol-1-yl)pentyl]phenyl]acetyl)-L-seryl-N-(2-cyclohexylethyl)-L-lysinamide
-
 Candida albicans
2.3.1.97 N-([4-[5-(2-methyl-1H-imidazol-1-yl)pentyl]phenyl]acetyl)-L-seryl-N-(2-cyclohexylethyl)-L-lysinamide
-
 Cryptococcus neoformans
2.3.1.97 N-([4-[5-(2-methyl-1H-imidazol-1-yl)pentyl]phenyl]acetyl)-L-seryl-N-(2-cyclohexylethyl)-L-lysinamide
-
 Histoplasma capsulatum
2.3.1.97 N-([4-[5-(2-methyl-1H-imidazol-1-yl)pentyl]phenyl]acetyl)-L-seryl-N-(2-cyclohexylethyl)-L-lysinamide
-
 Leishmania major
2.3.1.97 N-([4-[5-(2-methyl-1H-imidazol-1-yl)pentyl]phenyl]acetyl)-L-seryl-N-(2-cyclohexylethyl)-L-lysinamide
-
 Plasmodium falciparum
2.3.1.97 N-([4-[5-(2-methyl-1H-imidazol-1-yl)pentyl]phenyl]acetyl)-L-seryl-N-(2-cyclohexylethyl)-L-lysinamide
-
 Saccharomyces cerevisiae
2.3.1.97 N-([4-[5-(2-methyl-1H-imidazol-1-yl)pentyl]phenyl]acetyl)-L-seryl-N-(2-cyclohexylethyl)-L-lysinamide
-
 Trypanosoma brucei
2.3.1.97 N-[(1R)-1-[3-(3-aminopropyl)-4-(2-cyclohexylethoxy)benzyl]-2-hydroxyethyl]-2-[4-[4-(2-methyl-1H-imidazol-1-yl)butyl]phenyl]acetamide
-
 Candida albicans
2.3.1.97 N-[(1R)-1-[3-(3-aminopropyl)-4-(2-cyclohexylethoxy)benzyl]-2-hydroxyethyl]-2-[4-[4-(2-methyl-1H-imidazol-1-yl)butyl]phenyl]acetamide
-
 Cryptococcus neoformans
2.3.1.97 N-[(1R)-1-[3-(3-aminopropyl)-4-(2-cyclohexylethoxy)benzyl]-2-hydroxyethyl]-2-[4-[4-(2-methyl-1H-imidazol-1-yl)butyl]phenyl]acetamide
-
 Histoplasma capsulatum
2.3.1.97 N-[(1R)-1-[3-(3-aminopropyl)-4-(2-cyclohexylethoxy)benzyl]-2-hydroxyethyl]-2-[4-[4-(2-methyl-1H-imidazol-1-yl)butyl]phenyl]acetamide
-
 Leishmania major
2.3.1.97 N-[(1R)-1-[3-(3-aminopropyl)-4-(2-cyclohexylethoxy)benzyl]-2-hydroxyethyl]-2-[4-[4-(2-methyl-1H-imidazol-1-yl)butyl]phenyl]acetamide
-
 Plasmodium falciparum
2.3.1.97 N-[(1R)-1-[3-(3-aminopropyl)-4-(2-cyclohexylethoxy)benzyl]-2-hydroxyethyl]-2-[4-[4-(2-methyl-1H-imidazol-1-yl)butyl]phenyl]acetamide
-
 Saccharomyces cerevisiae
2.3.1.97 N-[(1R)-1-[3-(3-aminopropyl)-4-(2-cyclohexylethoxy)benzyl]-2-hydroxyethyl]-2-[4-[4-(2-methyl-1H-imidazol-1-yl)butyl]phenyl]acetamide
-
 Trypanosoma brucei
2.3.1.97 S-(2-oxo)pentadecyl-CoA
-
 Candida albicans
2.3.1.97 S-(2-oxo)pentadecyl-CoA
-
 Cryptococcus neoformans
2.3.1.97 S-(2-oxo)pentadecyl-CoA
-
 Histoplasma capsulatum
2.3.1.97 S-(2-oxo)pentadecyl-CoA
-
 Leishmania major
2.3.1.97 S-(2-oxo)pentadecyl-CoA
-
 Plasmodium falciparum
2.3.1.97 S-(2-oxo)pentadecyl-CoA
-
 Saccharomyces cerevisiae
2.3.1.97 S-(2-oxo)pentadecyl-CoA
-
 Trypanosoma brucei
2.3.1.97 SC-58272 NMT inhibitor Candida albicans

Molecular Weight [Da]

EC Number Molecular Weight [Da] Molecular Weight Maximum [Da] Comment Organism
2.3.1.97 50000
-
 x * 50000, about, SDS-PAGE Saccharomyces cerevisiae

Organism

EC Number Organism UniProt Comment Textmining
2.3.1.97 Candida albicans
-
-
-
2.3.1.97 Cryptococcus neoformans
-
-
-
2.3.1.97 Histoplasma capsulatum
-
-
-
2.3.1.97 Leishmania major
-
-
-
2.3.1.97 Plasmodium falciparum
-
-
-
2.3.1.97 Saccharomyces cerevisiae
-
-
-
2.3.1.97 Trypanosoma brucei
-
-
-

Purification (Commentary)

EC Number Purification (Comment) Organism
2.3.1.97 native enzyme Saccharomyces cerevisiae

Reaction

EC Number Reaction Comment Organism Reaction ID
2.3.1.97 tetradecanoyl-CoA + an N-terminal-glycyl-[protein] = CoA + an N-terminal-N-tetradecanoylglycyl-[protein] myristoylation by NMT proceeds via an ordered bi-bi reaction mechanism in which binding of myristoyl-CoA generates a second binding pocket for the docking of the substrate protein. The myristate group from myristoyl-CoA is then transferred to the N-terminal glycine of the bound protein in a nucleophilic addition-elimination reaction. This is followed by stepwise release, first of the free CoA and then the N-myristoylated protein Saccharomyces cerevisiae
a
2.3.1.97 tetradecanoyl-CoA + an N-terminal-glycyl-[protein] = CoA + an N-terminal-N-tetradecanoylglycyl-[protein] myristoylation by NMT proceeds via an ordered bi-bi reaction mechanism in which binding of myristoyl-CoA generates a second binding pocket for the docking of the substrate protein. The myristate group from myristoyl-CoA is then transferred to the N-terminal glycine of the bound protein in a nucleophilic addition-elimination reaction. This is followed by stepwise release, first of the free CoA and then the N-myristoylated protein Trypanosoma brucei
a
2.3.1.97 tetradecanoyl-CoA + an N-terminal-glycyl-[protein] = CoA + an N-terminal-N-tetradecanoylglycyl-[protein] myristoylation by NMT proceeds via an ordered bi-bi reaction mechanism in which binding of myristoyl-CoA generates a second binding pocket for the docking of the substrate protein. The myristate group from myristoyl-CoA is then transferred to the N-terminal glycine of the bound protein in a nucleophilic addition-elimination reaction. This is followed by stepwise release, first of the free CoA and then the N-myristoylated protein Candida albicans
a
2.3.1.97 tetradecanoyl-CoA + an N-terminal-glycyl-[protein] = CoA + an N-terminal-N-tetradecanoylglycyl-[protein] myristoylation by NMT proceeds via an ordered bi-bi reaction mechanism in which binding of myristoyl-CoA generates a second binding pocket for the docking of the substrate protein. The myristate group from myristoyl-CoA is then transferred to the N-terminal glycine of the bound protein in a nucleophilic addition-elimination reaction. This is followed by stepwise release, first of the free CoA and then the N-myristoylated protein Plasmodium falciparum
a
2.3.1.97 tetradecanoyl-CoA + an N-terminal-glycyl-[protein] = CoA + an N-terminal-N-tetradecanoylglycyl-[protein] myristoylation by NMT proceeds via an ordered bi-bi reaction mechanism in which binding of myristoyl-CoA generates a second binding pocket for the docking of the substrate protein. The myristate group from myristoyl-CoA is then transferred to the N-terminal glycine of the bound protein in a nucleophilic addition-elimination reaction. This is followed by stepwise release, first of the free CoA and then the N-myristoylated protein Cryptococcus neoformans
a
2.3.1.97 tetradecanoyl-CoA + an N-terminal-glycyl-[protein] = CoA + an N-terminal-N-tetradecanoylglycyl-[protein] myristoylation by NMT proceeds via an ordered bi-bi reaction mechanism in which binding of myristoyl-CoA generates a second binding pocket for the docking of the substrate protein. The myristate group from myristoyl-CoA is then transferred to the N-terminal glycine of the bound protein in a nucleophilic addition-elimination reaction. This is followed by stepwise release, first of the free CoA and then the N-myristoylated protein Leishmania major
a
2.3.1.97 tetradecanoyl-CoA + an N-terminal-glycyl-[protein] = CoA + an N-terminal-N-tetradecanoylglycyl-[protein] myristoylation by NMT proceeds via an ordered bi-bi reaction mechanism in which binding of myristoyl-CoA generates a second binding pocket for the docking of the substrate protein. The myristate group from myristoyl-CoA is then transferred to the N-terminal glycine of the bound protein in a nucleophilic addition-elimination reaction. This is followed by stepwise release, first of the free CoA and then the N-myristoylated protein Histoplasma capsulatum
a

Substrates and Products (Substrate)

EC Number Substrates Comment Substrates Organism Products Comment (Products) Rev. Reac.
2.3.1.97 tetradecanoyl-CoA + GLYASKLA i.e. myristoyl-CoA Saccharomyces cerevisiae CoA + N-tetradecanoyl-GLYASKLA
-
 ?
2.3.1.97 tetradecanoyl-CoA + GLYASKLA i.e. myristoyl-CoA Trypanosoma brucei CoA + N-tetradecanoyl-GLYASKLA
-
 ?
2.3.1.97 tetradecanoyl-CoA + GLYASKLA i.e. myristoyl-CoA Candida albicans CoA + N-tetradecanoyl-GLYASKLA
-
 ?
2.3.1.97 tetradecanoyl-CoA + GLYASKLA i.e. myristoyl-CoA Plasmodium falciparum CoA + N-tetradecanoyl-GLYASKLA
-
 ?
2.3.1.97 tetradecanoyl-CoA + GLYASKLA i.e. myristoyl-CoA Cryptococcus neoformans CoA + N-tetradecanoyl-GLYASKLA
-
 ?
2.3.1.97 tetradecanoyl-CoA + GLYASKLA i.e. myristoyl-CoA Leishmania major CoA + N-tetradecanoyl-GLYASKLA
-
 ?
2.3.1.97 tetradecanoyl-CoA + GLYASKLA i.e. myristoyl-CoA Histoplasma capsulatum CoA + N-tetradecanoyl-GLYASKLA
-
 ?

Subunits

EC Number Subunits Comment Organism
2.3.1.97 ? x * 50000, about, SDS-PAGE Saccharomyces cerevisiae

Synonyms

EC Number Synonyms Comment Organism
2.3.1.97 myristoyl-CoA:protein N-myristoyltransferase
-
 Saccharomyces cerevisiae
2.3.1.97 myristoyl-CoA:protein N-myristoyltransferase
-
 Trypanosoma brucei
2.3.1.97 myristoyl-CoA:protein N-myristoyltransferase
-
 Candida albicans
2.3.1.97 myristoyl-CoA:protein N-myristoyltransferase
-
 Plasmodium falciparum
2.3.1.97 myristoyl-CoA:protein N-myristoyltransferase
-
 Cryptococcus neoformans
2.3.1.97 myristoyl-CoA:protein N-myristoyltransferase
-
 Leishmania major
2.3.1.97 myristoyl-CoA:protein N-myristoyltransferase
-
 Histoplasma capsulatum
2.3.1.97 N-myristoyltransferase
-
 Saccharomyces cerevisiae
2.3.1.97 N-myristoyltransferase
-
 Trypanosoma brucei
2.3.1.97 N-myristoyltransferase
-
 Candida albicans
2.3.1.97 N-myristoyltransferase
-
 Plasmodium falciparum
2.3.1.97 N-myristoyltransferase
-
 Cryptococcus neoformans
2.3.1.97 N-myristoyltransferase
-
 Leishmania major
2.3.1.97 N-myristoyltransferase
-
 Histoplasma capsulatum
2.3.1.97 NMT
-
 Saccharomyces cerevisiae
2.3.1.97 NMT
-
 Trypanosoma brucei
2.3.1.97 NMT
-
 Candida albicans
2.3.1.97 NMT
-
 Plasmodium falciparum
2.3.1.97 NMT
-
 Cryptococcus neoformans
2.3.1.97 NMT
-
 Leishmania major
2.3.1.97 NMT
-
 Histoplasma capsulatum